Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Mylan

Evaluate

Thumbnail
January 30, 2023

The copycats chasing Humira’s tail

Thumbnail
November 08, 2022

Makeover sees Viatris move further away from generics

The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.

Article image
Vantage logo
August 25, 2022

Did Sandoz prove too big a pill for private equity?

Article image
Vantage logo
July 14, 2022

Theravance gets a fresh start

Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.

Article image
Vantage logo
April 13, 2022

Takeover-driven resurgence fails to materialise for biotech

Deal making in biosimilars dominates a slow start to the year for biopharma M&A.

Article image
Vantage logo
March 11, 2022

Alvotech settlement completes the list of Humira challengers

Article image
Vantage logo
March 02, 2022

US FDA approval tracker: February 2022

Article image
Vantage logo
February 28, 2022

Another biosimilars retreat, this time from Viatris

Article image
Vantage logo
September 15, 2021

The other shoe drops for Theravance

Article image
Vantage logo
August 24, 2021

Theravance fails its first big test

A flop for the gut-selective Jak inhibitor izencitinib makes a Johnson & Johnson opt-in look unlikely.

Article image
Vantage logo
August 02, 2021

US FDA approval tracker: July 2021

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up